Patent number: 8076338
Abstract: The present invention relates to compounds of the Formula (I) and (II) wherein R, R21, R25-R33, m, n, X21-X23, and Q1 are defined herein. The compounds modulate protein kinase enzymatic activity to modulate cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly p70S6 and/or Akt kinases. Methods of using and preparing the compounds, and pharmaceutical compositions thereof, to treat kinase-dependent diseases and conditions are also an aspect of the invention.
Type:
Grant
Filed:
April 22, 2005
Date of Patent:
December 13, 2011
Assignee:
Exelixis, Inc.
Inventors:
Neel K. Anand, Charles M. Blazey, Owen Joseph Bowles, Joerg Bussenius, Lynne Canne Bannen, Diva Sze-Ming Chan, Baili Chen, Erick Wang Co, Simona Costanzo, Steven Charles Defina, Larisa Dubenko, Maurizio Franzini, Ping Huang, Vasu Jammalamadaka, Richard George Khoury, Moon Hwan Kim, Rhett Ronald Klein, Donna Tra Le, Morrison B. Mac, John M. Nuss, Jason Jevious Parks, Kenneth D. Rice, Tsze H. Tsang, Amy Lew Tsuhako, Yong Wang, Wei Xu
Patent number: 7704995
Abstract: This invention relates to compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion, and to pharmaceutical compositions containing such compounds. Even more specifically, the invention relates to compounds that inhibit, regulate and/or modulate kinases, particularly Checkpoint Kinases, even more particularly Checkpoint Kinase 1, or Chk1. Methods of therapeutically or prophylactically using the compounds and compositions to treat kinase-dependent diseases and conditions are also an aspect of the invention, and include methods of treating cancer, as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, by administering effective amounts of such compounds.
Type:
Grant
Filed:
May 2, 2003
Date of Patent:
April 27, 2010
Assignee:
Exelixis, Inc.
Inventors:
Chris A. Buhr, Tae-Gon Baik, Sunghoon Ma, Zerom Tesfai, Longcheng Wang, Erick Wang Co, Sergey Epshteyn, Abigail R Kennedy, Baili Chen, Larisa Dubenko, Neel Kumar Anand, Tsze H. Tsang, John M. Nuss, Csaba J Peto, Kenneth D. Rice, Mohamed Abdulkader Ibrahim, Kevin Luke Schnepp, Xian Shi, James William Leahy, Jeff Chen, Lisa Esther Dalrymple, Timothy Patrick Forsyth, Tai Phat Huynh, Grace Mann, Larry Wayne Mann, Craig Stacy Takeuchi, Peter Lamb, David J. Matthews, Nicole Miller
Publication number: 20080076774
Abstract: The present invention relates to compounds of the Formula (I) and (II) wherein R, R21, R25-R33, m, n, X21-X23, and Q1 are defined herein. The compounds modulate protein kinase enzymatic activity to modulate cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly p70S6 and/or Akt kinases. Methods of using and preparing the compounds, and pharmaceutical compositions thereof, to treat kinase-dependent diseases and conditions are also an aspect of the invention.
Type:
Application
Filed:
April 22, 2005
Publication date:
March 27, 2008
Applicant:
Exelixis, Inc.
Inventors:
Neel K. Anand, Charles M. Blazey, Owen Joseph Bowles, Joerg Bussenius, Lynne Canne Bannen, Diva Sze-Ming Chan, Baili Chen, Erick Wang Co, Simona Costanzo, Steven Charles Defina, Larisa Dubenko, Maurizio Franzini, Ping Huang, Vasu Jammalamadaka, Richard George Khoury, Moon Hwan Kim, Rhett Ronald Klein, Donna Tra Le, Morrison B. Mac, John M. Nuss, Jason Jevious Parks, Kenneth D. Rice, Tsze H. Tsang, Amy Lew Tsuhako, Yong Wang, Wei Xu
